DDL Diagnostic Laboratory
DDL Diagnostic Laboratory is recorded as a service provider in 15 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 15 of 15 trials · Latest update first
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Approximately 50% of the first 22 Part 1 participants experienced on-treatment ALT elevations, and protocol management criteria were amended because some elevations were prolonged.
- New enrollment was temporarily halted in December 2022 after significant ALT elevations were observed more frequently in Part 2 participants with screening or baseline HBsAg >10,000 IU/mL.
- Enrollment was not reopened because the sponsor discontinued further investment in its hepatitis B and D discovery and development programs.
- Part 2 open-label treatment was reduced to Week 96 and follow-up to 24 weeks under protocol amendment 5.
- Sustained HBV response was not collected or analyzed because follow-up was shortened and participants continued NA treatment during follow-up.
These findings describe the trial, not the service provider’s performance or responsibility.
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19
Sponsor Gilead Sciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- All 3 participants were enrolled at United States sites, with 2 participants in Cohort 1 and 1 in Cohort 2.
- Only 3 participants completed the prematurely stopped trial, so protocol-specified analyses could not be performed.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants with Chronic Hepatitis D Virus Infection (SOLSTICE)
Sponsor Vir Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)
Sponsor Vir Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study
Sponsor Atea Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection
Sponsor Vir Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)
Sponsor Vir Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tide analogue (NA) therapy.
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection
Sponsor Arbutus Biopharma Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for DDL Diagnostic Laboratory?
The 2026-10-09 snapshot links DDL Diagnostic Laboratory to 15 distinct CTIS trials. Recorded services include Laboratory services, Storage Specimens, Virology, HBcrAg analysis, resistance surveillance analysis, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for DDL Diagnostic Laboratory?
The most frequently recorded therapeutic areas are Infectious Disease, Hepatology, Gastroenterology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to DDL Diagnostic Laboratory conducted?
The linked trials record locations in 15 countries, including France, Romania, Germany, Spain, Italy. These are trial locations, not confirmed office locations or countries where DDL Diagnostic Laboratory delivered services.
What can this page tell me about DDL Diagnostic Laboratory's trial experience?
Browse 15 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under DDL Diagnostic Laboratory. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- DDL Diagnostic Laboratory B.V.